
Key Challenges in Eliminating Tuberculosis in India
Despite improvements in tuberculosis (TB) diagnosis and treatment, India continues to grapple with significant obstacles in achieving elimination by 2025. According to The Indian Express, India accounts for approximately one-quarter of the global TB burden.
Significant Bottlenecks
- Limited Access to Testing: Many people, particularly in rural and impoverished areas, lack access to rapid molecular testing and timely sample transportation, delaying diagnosis.
- Drug-Resistant TB: A substantial burden of drug-resistant TB complicates treatment and increases costs. Incomplete therapy, incorrect prescriptions, and irregular medication use contribute to antibiotic resistance.
- Patient Adherence: Long treatment durations, adverse drug effects, and socioeconomic difficulties can lead patients to abandon treatment, increasing the risk of recurrence, transmission, and resistance.
- Financial and Social Barriers: Economic hardship, inadequate housing, and lack of nutritional food exacerbate vulnerability among disadvantaged groups.
- Private Healthcare Gaps: Reliance on private healthcare providers can result in inconsistencies in diagnostic techniques, treatment regimens, and case reporting.
Progress and Current Estimates
Between 2015 and 2025, India’s TB mortality rate decreased by 38%, from 28 to 18 per lakh population. In 2025, rapid diagnostic tests accounted for 46% of detected cases, up from 38% in 2024. The TB Mukt Bharat Abhiyaan identified nearly 49 lakh new cases, including approximately 15 lakh asymptomatic cases.
The estimated tuberculosis prevalence is currently being reviewed following district-level sentinel surveillance in 2025. Lack of current national incidence estimates and delays in the annual India TB Report hinder accurate assessment of the disease burden.
The National TB Elimination Program
Moving beyond case detection, a sustained, community-driven approach with sufficient support through the National TB Elimination Program is critical to achieving TB-free India. This requires focusing on comprehensive disease prevention, nutritional security, affordable treatment, and improved healthcare delivery.
Production-Linked Incentive (PLI) Schemes
According to The Indian Express, the PLI scheme, initiated in 2020, is a key element of India’s industrial policy. It provides financial incentives to businesses based on increased domestic production and sales of goods manufactured in India, aiming to boost manufacturing capabilities and integrate the country into global value chains.
Role of PLI Schemes
- Capacity Building: PLI plans enable businesses to establish new manufacturing facilities and expand existing capacities.
Next Steps
According to The Indian Express, India missed its 2025 TB target. Further information regarding progress and the issuance of the annual India TB Report is needed. The source material indicates that views and suggestions can be shared at manas.srivastava@indianexpress.com.
Source: The Indian Express. Featured image credit: The Indian Express.
Leave a Reply